Full Library
Chronic Graft-Versus-Host Disease
Resource type
Book Section
Authors/contributors
- Sureda, Anna (Editor)
- Corbacioglu, Selim (Editor)
- Greco, Raffaella (Editor)
- Kröger, Nicolaus (Editor)
- Carreras, Enric (Editor)
- Wolff, Daniel (Author)
- Peric, Zinaida (Author)
- Lawitschka, Anita (Author)
Title
Chronic Graft-Versus-Host Disease
Abstract
Abstract
Chronic GVHD (cGVHD) is the most relevant cause of late non-relapse morbidity and subsequent mortality (approximately 25%) following allo-HCT (Grube et al. 2016). Its incidence is approximately 50% among all patients following allo-HCT and has increased during the last two decades due to increasing patient age and increasing use of unrelated and/or mismatched donors, RIC regimens, PBSC with application of standard GVHD prophylaxis (calcineurin inhibitor [CNI] + MMF or MTX) only (Arai et al. 2015). While the incidence of cGVHD is lower (6–40%) in children, its incidence rises to 60% as age increases (Baird et al. 2010; Sobkowiak-Sobierajska et al. 2022).
Book Title
The EBMT Handbook
Date
2024
Publisher
Springer International Publishing
Place
Cham
Pages
395-410
ISBN
978-3-031-44079-3 978-3-031-44080-9
Accessed
10/9/25, 7:24 PM
Language
en
Library Catalog
DOI.org (Crossref)
Extra
Citation
Wolff, D., Peric, Z., & Lawitschka, A. (2024). Chronic Graft-Versus-Host Disease. In A. Sureda, S. Corbacioglu, R. Greco, N. Kröger, & E. Carreras (Eds.), The EBMT Handbook (pp. 395–410). Springer International Publishing. https://doi.org/10.1007/978-3-031-44080-9_44
HEME-ONC AND CELLULAR THERAPIES
Link to this record